Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD

Completed

• Conditions: Irisin Gene Polymorphism in Type II Diabetic Patients

• Registration Number: NCT04957823
• Lead Sponsor: Sohag University

Brief Summary

This is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism and the presence and severity of coronary artery disease in patients with Type II DM.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-20
• Study First Submitted: 2021-07-03
• Study First Submitted QC: 2021-07-03
• Study First Posted: 2021-07-12
• Primary Completion: 2022-08-30
• Study Completion: 2023-10-30
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-27
• Last Update Posted: 2024-02-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• This study will include type II diabetic patients aged between 18 and 45 years old

Exclusion Criteria

1. Recent acute myocardial infarction.
2. patients with Heart Failure
3. Active infection
4. End stage renal failure (GFR < 30 ml/min) or on dialysis
5. Liver cell failure
6. Athletes or having heavy muscular exercise in the previous 3 days

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Irisin level	6 months	detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)
FNDC5 Genotyping	6 months	whether homogenetic or heterogenetic

Trial Locations

Locations (1)

Sohag uniersity hosoital; 🇪🇬 Sohag, Egypt